Thomas Schinecker, Barbara Schädler, Michael Heuer, Stephan Feldhaus, Peter Voser
Thomas Schinecker has been appointed as CEO of Roche Diagnostics and a member of the firm's corporate executive committee, effective August 1. He will succeed Michael Heuer, who is retiring at the end of July. Schinecker is currently head of Centralized and Point of Care Solutions at Roche Diagnostics. Previously, he was general manager for Roche Diagnostics Germany, and before that, he held various management positions in marketing and sales as well as product development at Roche Diagnostics. He holds a PhD in molecular biology from New York University.
Barbara Schädler will become head of group communications and a member of Roche's enlarged Corporate Executive Committee, effective October 1. She will succeed Stephan Feldhaus, who will leave Roche at the end of September. Schädler is currently head of communications and public affairs at E.ON. Previously, she held communications manager positions at Lufthansa, SAP, and the German Federal Ministry of Finance. She holds a master's degree in economics from the University of Mainz.
Peter Voser will step down from the board of directors of Roche at the end of June due to his additional role as interim CEO of ABB.
Amelia Warner
Predictive Oncology has appointed Amelia Warner as the interim chief operating officer of its Helomics subsidiary. Prior to joining Helomics, Warner founded Global Specimens Solutions in 2013. Before GSS, Warner served as CEO for Gentris. She has also served as head of clinical pharmacogenomics and clinical specimen management for Merck. In addition, she has served as chair of the Industry Pharmacogenomics Working Group.
Bartu Ahiska
Oxford Biodynamics has appointed Bartu Ahiska as senior vice president (commercial) to spearhead commercialization of the company's EpiSwitch technology platform. Ahisku joins OBD from the Knight Cancer Early Detection Advanced Research Center at Oregon Health & Science University in Portland, where he has been the manager of innovation, IP, and and commercialization since 2016. He was a cofounder and remains a non-executive director of Trogenex in San Diego, and was COO and CEO of cloud-computing company Approxy before its acquisition by Numecent.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.